XBiotech (XBIT) Net Margin (2020 - 2022)

XBiotech (XBIT) posted quarterly Net Margin of 1067.67% for Q4 2022, down 41.7% quarter-over-quarter from 753.45% in Q3 2022.

XBiotech (XBIT) Net Margin (2020 - 2022) Analysis & Trends

XBiotech's Net Margin history runs 3 years deep, the most recent figure standing at 1067.67% for Q4 2022.

In Q4 2022, Net Margin changed N/A year-over-year to 1067.67%; the TTM figure through Sep 2023 stood at 7733.0% (down 731068.0% YoY), while the FY2022 annual figure was 820.45%, down 73345.0% from the prior year.
Net Margin for Q4 2022 stood at 1067.67%, down from 753.45% in the prior quarter.
The five-year high for Net Margin was 5.51% in Q4 2020, with the low at 1079.0% in Q1 2022.
The 3-year median for Net Margin is 72.16% (2021), against an average of 360.19%.
The sharpest annual moves came in 2021 and 2022: Net Margin sank 4822 bps in 2021, then plunged 102605 bps in 2022.
XBiotech's Net Margin stood at 5.51% in 2020, then tumbled by 1410 bps to 72.16% in 2021, then tumbled by 1380 bps to 1067.67% in 2022.
Business Quant data shows XBIT's Net Margin at 1067.67% in Q4 2022, 753.45% in Q3 2022, and 761.05% in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	XBiotech	68.90 Mn	68.90 Mn	-	-

Download Data